TRY NOW

Enhance and accelerate your early stage research with trusted and comprehensive intelligence from Thomson Reuters.

Start your free trial in just two simple steps.

Get your FREE trial

Enrich your discovery science with market leading, manually curated scientific intelligence. Systems Biology, Preclinical, Biomarkers, Chemistry, Biology, and Pharmacology - and everything in between. Covered from the perspective that matters most – yours.
Customer Feedback
Customer Feedback

Annette Bakker, Chief Scientific Officer from CTF, explains the reasons why she likes to work with Thomson Reuters. Currently using MetaCore™ to identify disease treatment options.

Live & Recorded Training

Attend one of our regularly scheduled webinar training sessions for overviews of features, tools, and content – find the schedule here

Free Pathway Maps

Search or browse through a wide range of proprietary multi-step canonical pathway maps here.

Featured News

The latest news from Life Sciences Research
The future of COPD treatment

The future of COPD treatment

Our research shows greater focus on preventative therapies

Translational Medicine

Translational Medicine

Supplement-Size Doses of Antioxidants Hasten Lung Cancer Progression

Tet Proteins Erase Epigenetic Marks

Tet Proteins Erase Epigenetic Marks

It is (reasonably) common knowledge that DNA is written in a simple four-letter code: ACTG. Too simple, actually.

Blog Highlights

Read our latest blog posts

Drug Review Times Vary Widely from Country to Country

Drugmakers often complain about slow regulatory review times, pointing to specific drugs that were approved months, or even years, faster in one market than in ...

Understaffed CFDA at the Root of 18,000-Application Backlog, Delays to Market

Lack of proper staffing is the main reason for the huge drug approval backlog at the CFDA, which topped 18,000 applications last year. Though the ...

The Top Drugs of 2014

The roundup of 2014’s top-selling drugs is dominated by the most expensive of drugs to develop, the biologicals. The year’s best-selling drug was AbbVie’s Humira, ...

Whitepapers & Publications

View our recent whitepapers and publications

BioMarker White Paper

Biomarkers: An indispensible addition to the drug development toolkit

THE YEAR'S NEW DRUGS & BIOLOGICS, 2013: PART I

http://dx.doi.org/10.1358/dot.2014.50.1.2116673

Latest on Twitter

Latest on Linked In